Pierre Fabre at the JP Morgan Healthcare Conference: strategic partnerships to accelerate innovation and develop the company's R&D and product portfolio.
22 January 2025
From January 12 to 16, Eric Ducournau and his team were present at the key event for pharmaceuticals, biotechs and healthcare investors.
They took part in over 100 meetings with innovative companies, strategic partners and investors.
By participating in this latest edition of the JP Morgan Healthcare Conference, Pierre Fabre has reaffirmed its commitment to becoming a global player in the field of innovative medicines.
Open innovation at the heart of our growth strategy
More than fifteen partnerships with innovative companies have been signed since Pierre Fabre first took part in this key event for the pharmaceutical industry.
The company is pursuing its efforts to strengthen its position in the therapeutic areas of oncology, dermatology, urology and rare diseases. Discussions at JP Morgan will enable us to explore new opportunities in these fields at all stages of the product life cycle, from preclinical to market launch in the territories where Pierre Fabre operates commercially.
Consolidating partnerships for the future
Exchanges with several of our long-standing partners have also enabled us to consolidate our collaborations. The JP Morgan Conference is an opportunity for us to take stock of our progress and consider the next steps in our R&D and commercial development.
The team present had the opportunity to exchange views with Atara, originator of a cell therapy marketed in Europe; Pfizer, our partner in targeted therapies; Abbvie; and Scorpion Therapeutics, co-development partner in several oncology clinical programs.